Safety profile of topical VEGF neutralization at the cornea.
about
Corneal nerves in health and diseaseThe wound healing effects of vitamin A eye drops after a corneal alkali burn in ratsMulti-gene targeted antiangiogenic therapies for experimental corneal neovascularization.Nerve growth factor regulates neurolymphatic remodeling during corneal inflammation and resolution.Effects of rat anti-VEGF antibody in a rat model of corneal graft rejection by topical and subconjunctival routes.IL-17 and VEGF are necessary for efficient corneal nerve regeneration.Larger therapeutic window for steroid versus VEGF-A inhibitor in inflammatory angiogenesis: surprisingly similar impact on leukocyte infiltration.Topical Bevacizumab for the Treatment of Ocular Surface Squamous NeoplasiaEffect of subconjuctival and intraocular bevacizumab injection on angiogenic gene expression levels in a mouse model of corneal neovascularization.Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes.Novel aspects of corneal angiogenic and lymphangiogenic privilege.Applications of aptamers in nanodelivery systems in cancer, eye and inflammatory diseases.Genome-wide expression datasets of anti-VEGF and dexamethasone treatment of angiogenesis in the rat cornea.Transplantation of PEDF-transfected pigment epithelial cells inhibits corneal neovascularization in a rabbit model.Inhibition of multiple pathogenic pathways by histone deacetylase inhibitor SAHA in a corneal alkali-burn injury model.Post-trabeculectomy topical bevacizumab preventing bleb failure: a preliminary study.Effects of topical bevacizumab application on early bleb failure after trabeculectomy: observational case series.Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium.Bevacizumab diminishes experimental autoimmune encephalomyelitis by inhibiting spinal cord angiogenesis and reducing peripheral T-cell responses.Topical bevacizumab treatment in aniridia.Safety of antivascular endothelial growth factor administration in the ocular anterior segment in pterygium and neovascular glaucoma treatment: Systematic review and meta-analysis
P2860
Q27002347-1E0A590B-03E4-4F0B-AA61-8C11D7735799Q28579217-0963A054-04B8-44F1-949E-85414971502BQ33694084-F23DFD99-2287-4BE1-9C2E-C8024B243A1EQ34483220-1ACF1767-B437-4F95-9BDF-CB22594CDF26Q34493789-66C9DCA0-8468-44E4-A53B-63685DB96285Q34755584-E58CE1EA-2AD2-4189-A59D-3205B8EDADCBQ36065917-6BA6DB8B-9B72-4E5D-89E6-EB47D76FBB19Q36140280-6B7C4AC2-37F2-4962-8856-11CF9CA5787EQ37425259-0F73AEDB-11B1-424F-9B76-6FD0AD6D5B4BQ37549985-C5C6D533-41C9-404A-B2F0-24CCE1AC56BCQ37681157-FC015E95-7DA3-47A5-A0BF-ECDA7126D737Q37815481-79694482-382F-486C-BC84-0C54BBEFBBC5Q38623872-0D19D96D-1A89-4359-8866-E9905D84443CQ38908590-C99B53E8-A315-4AB3-9944-558CC9109167Q41454864-33191D14-E2DF-42FD-901A-E39A76878797Q42206872-4DECE7B3-C8C5-47B9-99F6-6CEB07123526Q42653010-C04E8359-83AD-41AC-BF19-6FC0B819FC18Q43215465-8680C13B-3F00-42D0-B190-81A3AF838FB3Q44916496-3B9BB2CF-7263-4329-ADB4-484DB0C51FAFQ47727967-F70CBD9E-8549-4C79-9881-8007EAABF99AQ58706505-D14FB57E-0DCE-4F08-B58B-72F7D14EB8BF
P2860
Safety profile of topical VEGF neutralization at the cornea.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Safety profile of topical VEGF neutralization at the cornea.
@en
Safety profile of topical VEGF neutralization at the cornea.
@nl
type
label
Safety profile of topical VEGF neutralization at the cornea.
@en
Safety profile of topical VEGF neutralization at the cornea.
@nl
prefLabel
Safety profile of topical VEGF neutralization at the cornea.
@en
Safety profile of topical VEGF neutralization at the cornea.
@nl
P2093
P356
P1476
Safety profile of topical VEGF neutralization at the cornea.
@en
P2093
Björn Bachmann
Carmen Rummelt
Felix Bock
Friedrich E Kruse
Jasmine Onderka
Tina Dietrich
P304
P356
10.1167/IOVS.07-1129
P407
P577
2009-01-17T00:00:00Z